 Lung cancer is the leading cause of death in the United States as well as worldwide. It is estimated that approximately 215,020 new cases of lung cancer will be diagnosed in the United States in 2008, with approximately 161,840 deaths 1. The great majority of the lung cancers are grouped as non small cell lung cancer NSCLC, and only 13 as small cell lung cancer. Most patients with NSCLC present with advanced disease 55 with stage IIIB or IV. The overall median survival of patients with advanced NSCLC treated with first line platinum based doublets is less than 12 months 8 10 months with a 1 year and 2 year survival of 33 and 11, respectively 2-4. Agents targeting epidermal growth factor receptor EGFR, matrix metalloproteinase, farnesyl transferase, protein kinase C and retinoic X receptor have so far shown no survival benefit in combination with chemotherapy in advanced NSCLC 5-10. 